McIlrath & Eck’s Health Catalyst HCAT Stock Holding History

McIlrath & Eck’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48	Hold	38	–	–	﹤0.01%	1599
2025 Q4	$91	Hold	38	–	–	﹤0.01%	969
2025 Q3	$108	Hold	38	–	–	﹤0.01%	930
2025 Q2	$143	Hold	38	–	–	﹤0.01%	915
2025 Q1	$172	Hold	38	–	–	﹤0.01%	912
2024 Q4	$269	Hold	38	–	–	﹤0.01%	952
2024 Q3	$309	Hold	38	–	–	﹤0.01%	946
2024 Q2	$243	Hold	38	–	–	﹤0.01%	922
2024 Q1	$286	Hold	38	–	–	﹤0.01%	910
2023 Q4	$352	Hold	38	–	–	﹤0.01%	893
2023 Q3	$385	Hold	38	–	–	﹤0.01%	853
2023 Q2	$475	Hold	38	–	–	﹤0.01%	855
2023 Q1	$443	Hold	38	–	–	﹤0.01%	888
2022 Q4	$404	Hold	38	–	–	﹤0.01%	839
2022 Q3	$0	Hold	38	–	–	﹤0.01%	865
2022 Q2	$1K	Hold	38	–	–	﹤0.01%	778
2022 Q1	$1K	Hold	38	–	–	﹤0.01%	766
2021 Q4	$2K	Hold	38	–	–	﹤0.01%	720
2021 Q3	$2K	Buy	+38	New	+$2.07K	﹤0.01%	722

Other funds holding HCAT

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

CDC Financial Chicago, Illinois $157M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return

PVM

Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

McIlrath & Eck's HCAT Position: Q1 2026 in Review

McIlrath & Eck held its Health Catalyst (HCAT) position steady in Q1 2026 at 38 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #1599.

McIlrath & Eck first reported a position in HCAT in Q3 2021 and has held it in 19 quarters since. The position peaked at $2K in Q4 2021. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

McIlrath & Eck held 38 shares of Health Catalyst worth $48 as of Q1 2026.
McIlrath & Eck left its Health Catalyst share count unchanged in Q1 2026.
Health Catalyst made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1599 holding.
McIlrath & Eck first reported a position in Health Catalyst in Q3 2021 and has held it in 19 quarters since.
McIlrath & Eck's Health Catalyst position peaked at $2K in Q4 2021.
130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.